Comprehensive Study Guide on Platelet Physiology, Hemostasis, Blood Coagulation, and Transfusion Medicine

Platelets: Structure, Composition, and Physical Characteristics

• Definition: Platelets (thrombocytes) are colorless, non-nucleated, moderately refractive formed elements of blood, formed as detached fragments of cytoplasm.

• Dimensions and Volume:

  • Diameter: $2.5\,\mu$ (range of $2\text{ to }4\,\mu$).

  • Volume: $7.5\text{ cup}$ (range of $7\text{ to }8\text{ cup}$).

• Shape:

  • Inactivated platelets maintain a spherical, rod-shaped, oval, or disk-like morphology.

  • Other observed unusual shapes include dumb-bell, comma, and cigar shapes.

• Structural Architecture:

  • Cell Membrane: A $6\,\text{nm}$ thick membrane containing lipids (phospholipids, cholesterol, glycolipids), carbohydrates present as a glycocalyx layer, glycoproteins, and proteins.

  • Microtubules: Form a ring around the cytoplasm situated directly beneath the cell membrane. Composed of the protein tubulin, providing structural support to preserve the disk-like shape of inactivated platelets.

  • Cytoplasm: Houses cell organelles including the Golgi apparatus, endoplasmic reticulum, mitochondria, microtubules, microvessels, filaments, and granules.

• Cytoplasmic Chemical Components:

  • Contractile Proteins:

  • Actin and Myosin: Responsible for platelet contraction.

  • Thrombosthenin: The third contractile protein, responsible for clot retraction.

  • von Willebrand Factor: Responsible for platelet adherence.

  • Fibrin Stabilizing Factor: A blood clotting factor.

  • Platelet Derived Growth Factor (PDGF): Responsible for wound healing and the repair of damaged blood vessels.

  • Platelet Activating Factor (PAF): Causes aggregation of platelets during blood vessel injury.

  • Vitronectin (Serum Spreading Factor): Promotes platelet adhesion and spreading of cells in culture.

  • Thrombospondin: Inhibits angiogenesis (the formation of new blood vessels).

  • Enzymes: ATPase and essential enzymes required for prostaglandin synthesis.

  • Hormonal Substances: Adrenaline, 5-HT (serotonin), and histamine.

  • Other Substances: Glycogen, blood group antigens, and inorganic ions (calcium, copper, magnesium, and iron).

• Platelet Granules:

  • Alpha Granules: Contain clotting factor V, clotting factor XIII, fibrinogen, and platelet derived growth factor (PDGF).

  • Dense Granules: Contain nucleotides, serotonin, phospholipid, calcium, and lysosomes.

Physiological and Pathological Variations of Platelets

• Normal Platelet Count: Normal count is $2,50,000/\text{cumm}$ of blood, with a normal range between $2,00,000/\text{cumm}$ and $4,00,000/\text{cumm}$.

• Physiological Variations:

  • Age: Platelets are lower in infants, ranging from $1,50,000/\text{cumm}$ to $2,00,000/\text{cumm}$, reaching normal adult levels by the $3\text{rd}$ month after birth.

  • Sex: No baseline difference between males and females; however, the count decreases during menstruation in females.

  • Altitude: Platelet count increases at high altitudes.

  • Postprandial: Platelet count increases following food intake.

• Development (Thrombopoiesis):

  • Platelets originate in the bone marrow from pluripotent stem cells, which differentiate into CFU-M (Colony Forming Unit - Megakaryocyte) and subsequently into megakaryocytes.

  • Pseudopodia extend from the megakaryocyte cytoplasm; portions of these pseudopodia detach to form functional platelets that enter the systemic circulation.

  • Production is regulated by thrombopoietin, a glycoprotein hormone similar to erythropoietin, synthesized and secreted by the liver and kidneys.

• Lifespan and Fate:

  • The average lifespan of a platelet is approximately $10\text{ days}$.

  • Aged platelets are removed and destroyed by the tissue macrophage system located in the spleen.

Functional Properties and Roles of Platelets

• Functional Properties:

  • Adhesiveness: The property of sticking to a rough surface upon activation following contact.

  • Aggregation: The grouping together of activated, sticky platelets.

  • Agglutination: The clumping together of platelets.

• Physiological Roles:

  • Blood Clotting: Responsible for forming intrinsic prothrombin activator, which initiates the blood clotting cascade.

  • Clot Retraction: Mediated by cytoplasmic contractile proteins (actin, myosin, thrombosthenin) that contract the entrapped platelet network within fibrin threads.

  • Prevention of Blood Loss (Hemostasis):

  • Secrete 5-HT (serotonin) to induce blood vessel constriction.

  • Seal minor blood vessel damage (such as in capillaries) via their adhesive property.

  • Form a temporary hemostatic plug to close damaged vessel walls.

  • Vessel Repair: PDGF released from cytoplasm repairs the vascular endothelium and surrounding damaged vessel structures.

  • Defense Mechanism: Encircle foreign bodies via agglutination and eliminate them through phagocytosis.

Applied Physiology: Platelet Disorders

• Thrombocytopenia:

  • Defined as a decrease in the platelet count below normal, leading to thrombocytopenic purpura.

  • Etiological conditions include: acute infections, acute leukemia, aplastic anemia, pernicious anemia, chickenpox, smallpox, splenomegaly, scarlet fever, typhoid, tuberculosis, and purpura.

• Thrombocytosis:

  • Defined as an increase in the platelet count.

  • Etiological conditions include: allergic conditions, hemorrhage, bone fractures, surgical operations, splenectomy, rheumatic fever, and trauma (wound/injury from external force).

• Thrombocythemia:

  • A condition characterized by a persistent and abnormal elevation in platelet count.

  • Occurs in: carcinoma, chronic leukemia, and Hodgkin's disease.

• Glanzmann Thrombasthenia:

  • An inherited hemorrhagic disorder caused by structural or functional abnormalities of platelets, leading to thrombasthenic purpura.

Hemostasis and Vascular Response

• Definition: Hemostasis is defined as the arrest or stoppage of bleeding from an injured blood vessel.

• Stages of Hemostasis:

  • Stage 1: Vasoconstriction:

  • Arterioles and small arteries constrict immediately post-injury as a local physiological response.

  • Damage to the vascular endothelium exposes subendothelial collagen.

  • von Willebrand factor accelerates the adherence of platelets to exposed collagen.

  • Activated platelets secrete serotonin and other vasoconstrictors (ADP, thromboxane A2) to reduce vessel lumen size and blood loss.

  • Stage 2: Formation of Platelet Plug:

  • Adhered platelets secrete ADP and thromboxane A2, which recruit and activate additional platelets.

  • Recruited platelets aggregate to form a loose, temporary hemostatic plug over the injury site.

  • Platelet aggregation is accelerated by Platelet Activating Factor (PAF).

  • Stage 3: Coagulation of Blood:

  • Conversion of soluble fibrinogen into an insoluble fibrin meshwork that anchors to the temporary plug, completely sealing the vascular rupture.

Blood Coagulation Factors

• Definition of Coagulation: Process by which blood loses its fluidity and transforms into a jelly-like mass several minutes after exposure or collection.

• Clotting Factors: Coagulation proceeds via a cascade of inactive proenzymes activated into functional enzymes.

  • Factor I: Fibrinogen

  • Factor II: Prothrombin

  • Factor III: Thromboplastin (Tissue factor)

  • Factor IV: Calcium

  • Factor V: Labile factor (Proaccelerin or Accelerator globulin)

  • Factor VI: Presence has not been proved

  • Factor VII: Stable factor

  • Factor VIII: Antihemophilic factor (Antihemophilic globulin)

  • Factor IX: Christmas factor (named after the patient in whom it was discovered)

  • Factor X: Stuart-Prower factor

  • Factor XI: Plasma thromboplastin antecedent

  • Factor XII: Hegman factor (Contact factor)

  • Factor XIII: Fibrin stabilizing factor (Fibrinase)

Mechanisms of Blood Coagulation: Enzyme Cascade Theory

• Enzyme Cascade Theory: Explains how coagulation factors exist as inactive proenzymes that are sequentially converted into active enzymes in a stepwise cascade until thrombin is formed.

• Stage 1: Formation of Prothrombin Activator:

  • Intrinsic Pathway:

  • Initiated by factors present within the vascular compartment (blood contact with exposed collagen).

  • Factor XII (Hegman factor) contacts exposed collagen, converting to active Factor XIIa in the presence of kallikrein and high molecular weight (HMW) kinogen.

  • Factor XIIa converts Factor XI into active Factor XIa in the presence of HMW kinogen.

  • Factor XIa activates Factor IX in the presence of Factor IV ($\text{calcium}$).

  • Factor IXa activates Factor X in the presence of Factor VIII and calcium.

  • Activated Factor Xa combines with platelet phospholipids, Factor V, and calcium ions to form the prothrombin activator complex.

  • Factor V is further activated by a positive feedback action of thrombin.

  • Extrinsic Pathway:

  • Initiated by tissue thromboplastin (Factor III) released from traumatized extra-vascular tissues.

  • Tissue thromboplastin contains proteins, phospholipids, and glycoproteins that function as proteolytic enzymes.

  • Glycoprotein and phospholipid components of tissue thromboplastin activate Factor X to Factor Xa in the presence of Factor VII.

  • Factor Xa reacts with Factor V, calcium ions, and the phospholipid component of tissue thromboplastin to yield prothrombin activator.

• Stage 2: Conversion of Prothrombin into Thrombin:

  • Prothrombin activator generated from either pathway converts prothrombin to active thrombin in the presence of Factor IV ($\text{calcium}$).

  • Positive Feedback Effect: Formed thrombin stimulates Factor V activation, which accelerates both intrinsic and extrinsic prothrombin activator formation, generating exponentially more thrombin.

• Stage 3: Conversion of Fibrinogen into Fibrin:

  • Thrombin cleaves fibrinogen into activated fibrinogen (fibrin monomers).

  • Fibrin monomers spontaneously polymerize into loose fibrin strands.

  • Factor XIII (Fibrin stabilizing factor) converts loose strands into tight, cross-linked fibrin threads in the presence of calcium ions, forming a stable blood clot meshwork.

Blood Clot, Clot Retraction, and Fibrinolysis

• Blood Clot Structure: A mesh of fibrin threads entangling red blood cells, white blood cells, and platelets.

• Clot Retraction:

  • Within $30\text{ to }45\text{ minutes}$ post-formation, the clot undergoes contraction, expressing a clear, straw-colored fluid termed serum.

  • Retraction is driven by platelet cytoplasmic contractile proteins: actin, myosin, and thrombosthenin.

• Fibrinolysis:

  • The physiological dissolution of an intravascular blood clot to restore vessel lumen patency.

  • Mediated by plasmin (fibrinolysin), derived from its inactive precursor plasminogen (synthesized in the liver and incorporated into the clot).

  • Plasminogen is activated to plasmin by tissue plasminogen activator (t-PA), lysosomal enzymes, and thrombin.

  • Plasmin enzymatically digests and dissolves fibrin threads.

  • Clinical Significance: Prevents tissue necrosis and myocardial infarction by re-opening obstructed microvessels. Recombinant or exogenous enzymes such as streptokinase are administered clinically during early stages of acute myocardial infarction.

Anticlotting Mechanisms and Anticoagulants

• In Vivo Anticlotting Mechanisms:

  • Physical Factors: Continuous movement/circulation of blood; smooth integrity of vascular endothelial lining.

  • Chemical Factors:

  • Presence of endogenous heparin secreted by liver mast cells and basophils.

  • Endothelial production of thrombomodulin (absent in brain capillaries), which binds thrombin to form a complex that activates Protein-C. Protein-C, alongside cofactor Protein-S, inactivates Factor V and Factor VIII.

  • Circulation of clotting factors in inactive proenzyme forms.

• Pharmacological and Laboratory Anticoagulants:

  • Heparin:

  • Produced by mast cells (located in connective tissues surrounding capillaries, abundant in liver and lungs) and basophils.

  • Conjugated polysaccharide available commercially as sodium, calcium, ammonium, or lithium salts.

  • Mechanism: Exhibits direct antithrombin activity; binds and activates antithrombin III to remove thrombin; inactivates active Factors IX, X, XI, and XII.

  • Clinical Administration: Intravenous injection of $0.5\text{ to }1\,\text{mg/kg}$ body weight delays clotting for $3\text{ to }4\text{ hours}$ until degraded by heparinase. Used in vivo during surgery, artificial kidney hemodialysis, heart-lung bypass surgery, blood preservation, and in vitro laboratory procedures. Most expensive anticoagulant.

  • Coumarin Derivatives (Dicoumoral and Warfarin):

  • Function as oral in vivo anticoagulants by inhibiting Vitamin K, which is required for hepatic synthesis of Factors II, VII, IX, and X.

  • EDTA (Ethylenediaminetetraacetic Acid):

  • Available as disodium salt ($\text{Na}_2\text{ EDTA}$) or tripotassium salt ($\text{K}_3\text{ EDTA}$).

  • Prevents clotting by chelating/removing free calcium ions. Administered intravenously for lead poisoning (in vivo) and used in laboratory testing (in vitro).

  • Oxalate Compounds:

  • In vitro anticoagulant mixture of ammonium oxalate and potassium oxalate in a $3:2$ ratio. Potassium oxalate alone causes RBC shrinkage, while ammonium oxalate alone causes RBC swelling; the $3:2$ combination prevents cell volume alterations.

  • Precipitates calcium as insoluble calcium oxalate. Highly toxic; forbidden for in vivo use.

  • Citrates:

  • Sodium, potassium, and ammonium salts of citrate bind calcium to form insoluble calcium citrate.

  • Used in vitro for hematological counts and in vivo/in vitro for blood bank storage as Acid Citrate Dextrose (ACD) or Citrate Phosphate Dextrose (CPD).

  • Other Anticoagulants: Peptone, copperhead snake venom proteins, and hirudin (extracted from leeches).

Physical Methods, Procoagulants, and Coagulation Diagnostics

• Physical Methods to Prevent Clotting:

  • Cold: Lowering blood temperature to $5^\circ\text{C}$ delays coagulation.

  • Smooth Surfaces: Collecting blood in silicon-coated containers prevents Factor XII and platelet contact activation, suppressing prothrombin activator generation.

• Procoagulants (Hemostatic Agents):

  • Substances that accelerate blood coagulation: thrombin, snake venom, tissue extracts of lung and thymus, sodium or calcium alginate, and oxidized cellulose.

• Diagnostic Clotting Tests:

  • Bleeding Time:

  • Time interval from initial bleeding after injury until total arrest of bleeding.

  • Measured via the Duke method using filter/blotting paper.

  • Normal Range: $3-6\text{ minutes}$. Prolonged specifically in purpura.

  • Clotting Time:

  • Time interval from blood oozing to visible clot formation.

  • Measured via the capillary tube method.

  • Normal Range: $3-8\text{ minutes}$. Prolonged specifically in hemophilia.

  • Prothrombin Time:

  • Time taken for oxalated blood to clot after re-calcification and addition of excess tissue thromboplastin.

  • Evaluates overall prothrombin content and extrinsic pathway integrity.

  • Normal Duration: Approximately $12\text{ seconds}$. Prolonged in deficiencies of prothrombin, Factor I, Factor V, Factor VII, and Factor X. Unaffected (normal) in hemophilia.

Applied Physiology: Bleeding Disorders and Thrombosis

• Hemophilia:

  • Sex-linked inherited group of disorders characterized by prolonged clotting time, affecting males while females act as asymptomatic carriers.

  • Caused by failure of prothrombin activator formation due to specific factor deficiencies.

  • Hemophilia A (Classic Hemophilia): Caused by Factor VIII deficiency; accounts for $85\%$ of hemophilia cases.

  • Hemophilia B (Christmas Disease): Caused by Factor IX deficiency; accounts for $15\%$ of hemophilia cases.

  • Hemophilia C: Caused by Factor XI deficiency; extremely rare.

• Purpura:

  • Disorder characterized by prolonged bleeding time with a normal clotting time, manifesting as spontaneous subepidermal/subcutaneous capillary hemorrhages called purpuric spots.

  • Thrombocytopenic Purpura: Due to reduced platelet count (thrombocytopenia) secondary to bone marrow disease.

  • Idiopathic Thrombocytopenic Purpura: Caused by anti-platelet autoantibodies developed post-transfusion.

  • Thrombasthenic Purpura: Platelet count is normal, but structural or functional platelet defects lead to abnormal bleeding time and defective clot retraction.

• von Willebrand Disease:

  • Inherited deficiency of von Willebrand factor, impairing platelet-collagen adhesion and reducing plasma Factor VIII stability/half-life, resulting in combined clinical features of platelet dysfunction and hemophilia.

• Thrombosis:

  • Pathological intravascular blood coagulation.

  • Etiological Factors: Vessel injury, endothelial roughness, sluggish blood flow, RBC agglutination, toxic poisons (snake venom, mercury, arsenic), or congenital absence of Protein-C.

  • Complications:

  • Thrombus: Vascular occlusive mass formed by platelets, fibrin, and blood cells. Agglutination of RBCs creates an agglutinative thrombus.

  • Embolism and Embolus: Detached thrombus fragment (embolus) traveling through circulation to occlude distal microvessels (e.g., pulmonary, cerebral, or coronary embolism).

  • Ischemia: Inadequate tissue perfusion causing cellular hypoxia, severe pain, and tissue death.

  • Necrosis and Infarction: Tissue necrosis resulting from arterial occlusion by a thrombus or embolus. Infarcted area is termed an infarct, commonly occurring in the heart, brain, lungs, kidneys, and spleen.

ABO Blood Group System and Landsteiner's Law

• Historical Context: Discovered in 1901 by Karl Landsteiner (awarded the Nobel Prize in 1930) based on red cell agglutination reactions.

• Landsteiner's Law:

  • If a specific antigen (agglutinogen) is present on the RBC membrane, the corresponding antibody (agglutinin) must be absent from the serum.

  • If a specific antigen is absent from the RBC membrane, the corresponding antibody must be present in the serum (Note: the second part does not apply to the Rh system).

• ABO Group Classifications:

  • Group A: Contains A antigen on RBCs and anti-B ($\beta$) antibody in serum. Subgroups include $A_1$ and $A_2$.

  • Group B: Contains B antigen on RBCs and anti-A ($\alpha$) antibody in serum.

  • Group AB: Contains both A and B antigens on RBCs and no antibodies in serum. Subgroups include $A_1B$ and $A_2B$. Functions as the universal recipient.

  • Group O: Contains neither A nor B antigen on RBCs and both anti-A and anti-B antibodies in serum. Functions as the universal donor.

• Population Distributions:

  • Europeans: Group A ($42\%$), Group B ($9\%$), Group AB ($3\%$), Group O ($46\%$).

  • Asians: Group A ($25\%$), Group B ($25\%$), Group AB ($5\%$), Group O ($45\%$).

Typing, Inheritance, and Transfusion Reactions of ABO Groups

• Blood Typing (Matching) Procedure:

  • Suspension of patient RBCs in $0.9\%$ isotonic saline mixed separately with Antiserum A (containing anti-A) and Antiserum B (containing anti-B) on a slide.

  • Agglutination (visible clumping) with Antiserum A indicates Group A; with Antiserum B indicates Group B; with both antisera indicates Group AB; with neither antiserum indicates Group O.

• Cross Matching:

  • Performed prior to transfusion by mixing recipient serum directly with donor RBCs to confirm in vitro compatibility.

• Genetics and Inheritance:

  • ABO blood type is governed by co-dominant genes A and B, and recessive gene O.

  • Genotype combinations: $AA$ or $AO$ (Group A); $BB$ or $BO$ (Group B); $AB$ (Group AB); $OO$ (Group O).

• Transfusion Reactions (ABO Incompatibility):

  • Transfusion of mismatched donor RBCs leads to immediate immune agglutination and intravascular hemolysis by recipient plasma antibodies.

  • Jaundice: Rapid elevation of plasma bilirubin above $2\,\text{mg/dL}$ following massive hemoglobin breakdown.

  • Cardiac Shock: Released free hemoglobin increases blood viscosity, overloading the heart and inducing acute heart failure.

  • Renal Shutdown: Circulating cell toxins induce renal vasoconstriction; filtered hemoglobin and toxic products precipitate within renal tubules, causing tubular blockade, complete anuria, and death within $10-12\text{ days}$.

Rh Factor, Rh Incompatibility, and Erythroblastosis Fetalis

• Rh Factor Properties:

  • Discovered by Landsteiner and Wiener in rhesus monkeys. D antigen is the most potent human immunogen.

  • $85\%$ of Asians are Rh positive ($DD$ or $Dd$), while $15\%$ are Rh negative ($dd$).

  • Anti-D antibodies are not naturally present; they develop only after exposure of an Rh-negative individual to Rh-positive blood.

• Rh Incompatibility Reactions:

  • First Exposure: Initial exposure of an Rh-negative recipient to Rh-positive blood induces delayed formation of anti-D antibodies without immediate severe symptoms.

  • Second Exposure: Pre-existing anti-D antibodies cause rapid, severe agglutination and hemolysis of transfused Rh-positive cells, mirroring ABO transfusion reactions.

• Erythroblastosis Fetalis (Hemolytic Disease of the Newborn):

  • Occurs when an Rh-negative mother carries an Rh-positive fetus (inherited from an Rh-positive father).

  • First pregnancies usually proceed normally as fetal RBCs do not cross the intact placental barrier.

  • At delivery, placental detachment allows fetal Rh-positive RBCs to enter maternal circulation, stimulating maternal anti-D antibody production post-partum.

  • In a subsequent Rh-positive pregnancy, maternal anti-D IgG antibodies cross the placenta, inducing extensive fetal intra-vascular hemolysis.

  • Compensatory extramedullary hematopoiesis in the fetal liver and spleen releases large numbers of nucleated proerythroblasts (erythroblasts) into fetal circulation.

  • Pathological Consequences:

  • Severe Anemia: Can be fatal to the fetus/infant.

  • Hydrops Fetalis: Widespread fetal edema, hepatosplenomegaly, and heart failure, leading to intrauterine death.

  • Kernicterus: Severe unconjugated hyperbilirubinemia causes irreversible toxic precipitation within infant brain tissue.

• Prophylaxis and Management:

  • Administer anti-D immunoglobulin (RhoGAM) to Rh-negative mothers at the $28\text{th}$ and $34\text{th}$ weeks of gestation, and within $48\text{ hours}$ following delivery of an Rh-positive infant, to neutralize fetal antigens before maternal sensitization occurs.

  • Affected infants are treated via exchange transfusion, replacing infant Rh-positive blood with donor Rh-negative blood. The transfused cells persist for up to $6\text{ months}$, during which time maternal anti-D antibodies naturally decay.

Other Blood Group Systems and Transfusion Protocols

• Minor Blood Group Systems:

  • Clinically minor systems include: Lewis, MNS, Auber, Diego, Bombay, Duffy, Lutheran, P, Kell, I, Kidd, and Sulter XG.

• Indications and Precautions for Transfusion:

  • Indications: Severe anemia, acute hemorrhage, major trauma, deep burns, and surgical procedures.

  • Donor Screening: Donors must be screened for infectious agents such as syphilis and AIDS.

  • Administration Requirements: Transfusion equipment must be sterile; blood must be warmed to body temperature and infused slowly to avoid acute cardiac overload.

• Blood Substitutes: Intravenous solutions used to restore intravascular volume in place of whole blood, including human plasma, $0.9\%$ sodium chloride (saline) solution, and $5\%$ glucose solution.

• Exchange Transfusion: Complete replacement of patient blood volume with fresh donor blood or plasma, indicated in erythroblastosis fetalis, severe jaundice, and sickle cell anemia.

• Autologous Blood Transfusion: Collection and subsequent reinfusion of a patient's own blood (self-blood donation), as opposed to standard allogeneic (heterologous) transfusion from unrelated donors.